"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-Fort Worth Cancer Center conducted 86 clinical trials. In the 10-year time frame, 86 clinical trials started and 62 clinical trials were completed, i.e. on average, 72.1% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 34 clinical trials were completed. i.e. 87.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Fort Worth Cancer Center" #1 sponsor was "US Oncology Research" with 14 trials, followed by "Seagen Inc." with 10 trials sponsored, "Hoffmann-La Roche" with 9 trials sponsored, "Bristol-Myers Squibb" with 8 trials sponsored and "National Cancer Institute (NCI)" with 8 trials sponsored. Other sponsors include 110 different institutions and companies that sponsored additional 75 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Fort Worth Cancer Center" #1 collaborator was "NRG Oncology" with 8 trials as a collaborator, "Bristol-Myers Squibb" with 7 trials as a collaborator, "National Cancer Institute (NCI)" with 7 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 4 trials as a collaborator. Other collaborators include 52 different institutions and companies that were collaborators in the rest 47 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Fort Worth Cancer Center" are "Ovarian Cancer" (15 trials), "Breast Cancer" (12 trials), "Metastatic Breast Cancer" (9 trials), "Prostate Cancer" (9 trials) and "Colorectal Cancer" (8 trials). Many other conditions were trialed in "Texas Oncology-Fort Worth Cancer Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Fort Worth Cancer Center" are "Drug" (143 trials), "Other" (20 trials), "Biological" (19 trials), "Radiation" (9 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (16 trials), "Placebo" (14 trials), "Carboplatin" (13 trials), "Docetaxel" (10 trials) and "Nivolumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Fort Worth Cancer Center" are 106 trials for "All" genders, 39 trials for "Female" genders and 16 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Fort Worth Cancer Center". undefined are not yet recruiting, 28 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 83 completed trials in Texas Oncology-Fort Worth Cancer Center, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Fort Worth Cancer Center, 30 "Phase 1" clinical trials were conducted, 68 "Phase 2" clinical trials and 70 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".